On April 14, 2026, Revolution Medicines, Inc. entered into an underwriting agreement to offer 10,563,381 shares of common stock at $142.00 each, expecting to raise approximately $1.65 billion after expenses. Additionally, the company issued $500 million in Convertible Senior Notes due 2033, with both offerings expected to close shortly after on April 16 and 17, 2026.